Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
1
20%
Ph early_phase_1
1
20%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 13 (60.0%)
Phase 21 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

FX-322 in Adults With Acquired Sensorineural Hearing Loss

NCT05086276
completedphase_1

FX-322 in Sensorineural Hearing Loss

NCT03616223
completedphase_1

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

NCT04601909
completedphase_1

FX-322 in Adults With Severe Sensorineural Hearing Loss

NCT04629664
completedearly_phase_1

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

NCT03300687

Clinical Trials (5)

Showing 5 of 5 trials
NCT05086276Phase 2

FX-322 in Adults With Acquired Sensorineural Hearing Loss

Completed
NCT03616223Phase 1

FX-322 in Sensorineural Hearing Loss

Completed
NCT04601909Phase 1

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

Completed
NCT04629664Phase 1

FX-322 in Adults With Severe Sensorineural Hearing Loss

Completed
NCT03300687Early Phase 1

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5